Overview
PRLD market data
Price History
PRLD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.91 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -278.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.75 – $5.85 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $384.7M · P/B 2.39 · P/S 23.01.
Company News
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.Benzinga · Aug 11, 2026, 7:18 PM
8-K filing — Prelude Therapeutics Inc (PRLD)SEC EDGAR · Aug 11, 2026, 12:00 PM
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704MBenzinga · Aug 11, 2026, 11:23 AM
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price TargetBenzinga · Jul 29, 2026, 10:27 AM
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 28, 2026, 2:05 PM
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga · Jun 16, 2026, 12:10 PM